Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;12(8):231-238.
doi: 10.5489/cuaj.5462. Epub 2018 May 31.

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma

Affiliations

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma

Wassim Kassouf et al. Can Urol Assoc J. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Kassouf has received grants/honoraria from Astellas, AstraZeneca, Janssen, Merck, and Roche. Dr. Fairey has been a speaker for J&J and Roche. Dr. Finelli has attended advisory boards for AbbVie, Amgen, Astellas, Bayer, Janssen, Roche, and Sanofi. Dr. Kapoor has attended advisory boards for and participated in clinical trials supported by Amgen, Astellas, GSK, Janssen, Novartis, Pfizer, and Sanofi. Dr. Lattouf has attended advisory boards AbbVie, Amgen, Astellas, Novartis, and Pfizer; and has received an educational grant from Janssen. Dr. Leveridge has attended advisory boards for Astellas. Dr. Power has participated in clinical trials supported by Argos Therapeutics. Dr. Pouliot has attended advisory boards for, Amgen, Astellas, and Pfizer; has been a speaker for Sanofi; has received payment/grants/honoraria from Amgen, Astellas, Astra Zeneca, Janssen, Pfizer, and Sanofi. Dr. So has been a speaker for Amgen, Astellas, and Janssen. Dr. Tanguay has attended advisory boards for Pfizer; and has received travel grants from Sanofi. The remaining authors report no competing personal or financial interests.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Lucca I, Klatte T, Fajkovic H, et al. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol. 2015;12:585–92. doi: 10.1038/nrurol.2015.232. - DOI - PubMed
    1. Qayyum T, Oades G, Horgan P, et al. The epidemiology and risk factors for renal cancer. Curr Urol. 2013;6:169–74. doi: 10.1159/000343534. - DOI - PMC - PubMed
    1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57. doi: 10.1038/nrurol.2010.46. - DOI - PMC - PubMed
    1. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013;190:1657–61. doi: 10.1016/j.juro.2013.04.130. - DOI - PMC - PubMed

LinkOut - more resources